A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)
Start Date
6/22/2026
Completion Date
7/23/2035
Summary
Researchers are looking for new ways to treat follicular lymphoma (FL). A standard (usual) treatment for FL includes a targeted therapy called rituximab and chemotherapy. In this study, researchers want to learn if giving a study medicine called MK-1045 and rituximab can treat FL. MK-1045 is a type of treatment called immunotherapy. The goals of this study are to learn: * About the safety of MK-1045 and rituximab, and if people tolerate them when given together * If people who receive MK-1045 and rituximab have the cancer go away * If people who receive MK-1045 and rituximab live longer without their cancer getting worse compared to those who receive standard treatment (rituximab and chemotherapy)
Eligibility Criteria
Age Range: 18 years to No maximum
Interventions
MK-1045
Rituximab
Rituximab biosimilar
Bendamustine
Cyclophosphamide
Vincristine
Prednisone
Prednisolone
Doxorubicin Hydrochloride
Conditions
Locations
City of Hope - Duarte Cancer Center ( Site 1301)
Duarte, California 91010
United States
University of Kentucky ( Site 1303)
Lexington, Kentucky 40536
United States
John Theurer Cancer Center at Hackensack University Medical Center ( Site 1311)
Hackensack, New Jersey 07601
United States
Duke Cancer Center Clinic 1B/C Onc/Heme ( Site 1307)
Durham, North Carolina 27710
United States
SCRI Oncology Partners ( Site 7000)
Nashville, Tennessee 37203
United States
Instituto Alexander Fleming ( Site 0105)
Ciudad Autonoma de Buenos Aires, Buenos Aires C1426ANZ
Argentina
Hospital Aleman ( Site 0101)
Buenos Aires, Buenos Aires F.D. C1118AAT
Argentina
Sanatorio Nuestra Senora del Rosario ( Site 0104)
Rosario, Santa Fe Province S2001SBK
Argentina
Hospital Privado Universitario de Córdoba ( Site 0102)
Córdoba, X5016KEH
Argentina
Box Hill Hospital ( Site 0201)
Box Hill, Victoria 3128
Australia
Biocenter ( Site 0402)
Concepción, Biobio 4070196
Chile
Fundacion Arturo Lopez Perez FALP ( Site 0404)
Santiago, Region M. de Santiago 7500836
Chile
Beijing Cancer hospital ( Site 0501)
Beijing, Beijing Municipality 100142
China
Fudan University Shanghai Cancer Center ( Site 0504)
Shanghai, Shanghai Municipality 200030
China
Evangelismos General Hospital of Athens ( Site 1501)
Athens, Attica 106 76
Greece
General Hospital of Athens "Laiko" ( Site 1502)
Athens, Attica 115 27
Greece
Hadassah Medical Center ( Site 0701)
Jerusalem, 9112001
Israel
Sheba Medical Center ( Site 0702)
Ramat Gan, 5265601
Israel
Sourasky Medical Center ( Site 0704)
Tel Aviv, 6423906
Israel
Pratia MCM Krakow ( Site 1702)
Krakow, Lesser Poland Voivodeship 30-727
Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie ( Site 1701)
Warsaw, Masovian Voivodeship 02-781
Poland
Samsung Medical Center ( Site 0801)
Seoul, 06351
South Korea
Institut Català d'Oncologia (ICO) - Badalona ( Site 0904)
Badalona, Barcelona 08916
Spain
Hospital Virgen de la Victoria ( Site 0905)
Málaga, Malaga 29010
Spain
Hospital Universitari Vall de Hebron ( Site 0903)
Barcelona, 08035
Spain
Hospital Universitario Gregorio Maranon ( Site 0902)
Madrid, 28007
Spain
Hospital Universitario de Salamanca ( Site 0906)
Salamanca, 37007
Spain
National Taiwan University Hospital ( Site 1001)
Taipei, 100225
Taiwan
Chang Gung Medical Foundation-Linkou Branch ( Site 1002)
Taoyuan, 333
Taiwan
Hacettepe Universite Hastaneleri ( Site 1110)
Ankara, 06230
Turkey (Türkiye)
Sisli Florence Nightingale Hastanesi ( Site 1112)
Istanbul, 34381
Turkey (Türkiye)
Ondokuz Mayıs Universitesi ( Site 1113)
Samsun, 55270
Turkey (Türkiye)